Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01217203 | Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse | PHASE1 | COMPLETED | 15 | — | — | Sep 1, 2010 | Feb 1, 2014 | Feb 28, 2014 | 6 | United States |
safety of IPH2101 combined with lenalidomide at different dose levels.
| Arm | Type | Description |
|---|---|---|
| IPH2101 and lenalinomide | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IPH2101 combined to lenalidomide | DRUG | Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD) |
Inclusion Criteria: 1. Signed informed consent obtained before any trial-related activities 2. Progressive disease or relapse of multiple myeloma (according to the IMWG definition) after one or two prior therapeutic treatments or regimens for multiple myeloma that achieved a response duration of at...